Sintilimab for the treatment of non-small cell lung cancer

• Main Authors: Lin Zhang (Author), Weihao Lin (Author), Fengwei Tan (Author), Ning Li (Author), Qi Xue (Author), Shugeng Gao (Author), Yibo Gao (Author), Jie He (Author)
• Format: Book
• Published: BMC, 2022-04-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Abstract Anti-programmed death-1 (PD-1)/programmed death-ligand 1 (PD-L1) immunotherapy has dramatically changed the therapeutic landscape of inoperable non-small cell lung cancer (NSCLC), and has been included in first-line treatments. Sintilimab is a domestic anti-PD-1 monoclonal antibody in China...